Kiromic Biopharma Price To Book vs. Debt To Equity

KRBPDelisted Stock  USD 2.68  0.07  2.55%   
Based on the key profitability measurements obtained from Kiromic Biopharma's financial statements, Kiromic Biopharma may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess Kiromic Biopharma's ability to earn profits and add value for shareholders.
For Kiromic Biopharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Kiromic Biopharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Kiromic Biopharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Kiromic Biopharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Kiromic Biopharma over time as well as its relative position and ranking within its peers.
  
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
Please note, there is a significant difference between Kiromic Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kiromic Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kiromic Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Kiromic Biopharma Debt To Equity vs. Price To Book Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Kiromic Biopharma's current stock value. Our valuation model uses many indicators to compare Kiromic Biopharma value to that of its competitors to determine the firm's financial worth.
Kiromic Biopharma is currently regarded as number one stock in price to book category among its peers. It is rated below average in debt to equity category among its peers fabricating about  0.01  of Debt To Equity per Price To Book. The ratio of Price To Book to Debt To Equity for Kiromic Biopharma is roughly  73.69 . Comparative valuation analysis is a catch-all technique that is used if you cannot value Kiromic Biopharma by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Kiromic Debt To Equity vs. Price To Book

Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

Kiromic Biopharma

P/B

 = 

MV Per Share

BV Per Share

 = 
15.11 X
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

Kiromic Biopharma

D/E

 = 

Total Debt

Total Equity

 = 
0.20 %
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.

Kiromic Debt To Equity Comparison

Kiromic Biopharma is currently under evaluation in debt to equity category among its peers.

Kiromic Biopharma Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Kiromic Biopharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Kiromic Biopharma will eventually generate negative long term returns. The profitability progress is the general direction of Kiromic Biopharma's change in net profit over the period of time. It can combine multiple indicators of Kiromic Biopharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas. Kiromic Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 59 people.

Kiromic Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Kiromic Biopharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Kiromic Biopharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Kiromic Biopharma's important profitability drivers and their relationship over time.

Use Kiromic Biopharma in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kiromic Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kiromic Biopharma will appreciate offsetting losses from the drop in the long position's value.

Kiromic Biopharma Pair Trading

Kiromic Biopharma Pair Trading Analysis

The ability to find closely correlated positions to Kiromic Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kiromic Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kiromic Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kiromic Biopharma to buy it.
The correlation of Kiromic Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kiromic Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kiromic Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kiromic Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Kiromic Biopharma position

In addition to having Kiromic Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Agency Mbs ETFs Thematic Idea Now

Agency Mbs ETFs
Agency Mbs ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Agency Mbs ETFs theme has 11 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Agency Mbs ETFs Theme or any other thematic opportunities.
View All  Next Launch
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Other Consideration for investing in Kiromic Stock

If you are still planning to invest in Kiromic Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kiromic Biopharma's history and understand the potential risks before investing.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing